A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis

In TP53 wild-type acute myeloid leukemia (AML), inhibition of MDM2 can enhance p53 protein expression and potentiate leukemic cell apoptosis. MDM2 inhibitor (MDM2i) monotherapy in AML has shown modest responses in clinical trials but combining options of MDM2i with other potent AML-directed agents l...

Descripción completa

Detalles Bibliográficos
Autores principales: Senapati, Jayastu, Muftuoglu, Muharrem, Ishizawa, Jo, Abbas, Hussein A., Loghavi, Sanam, Borthakur, Gautam, Yilmaz, Musa, Issa, Ghayas C., Dara, Samuel I., Basyal, Mahesh, Li, Li, Naqvi, Kiran, Pourebrahim, Rasoul, Jabbour, Elias J., Kornblau, Steven M., Short, Nicholas J., Pemmaraju, Naveen, Garcia-Manero, Guillermo, Ravandi, Farhad, Khoury, Joseph, Daver, Naval, Kantarjian, Hagop M., Andreeff, Michael, DiNardo, Courtney D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310786/
https://www.ncbi.nlm.nih.gov/pubmed/37386016
http://dx.doi.org/10.1038/s41408-023-00871-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310786/
https://www.ncbi.nlm.nih.gov/pubmed/37386016
http://dx.doi.org/10.1038/s41408-023-00871-1

Ejemplares similares